Agomab Therapeutics NV — All Filings
25 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 3 | OWNERSHIP DOCUMENT | 0001104659-26-030839 | Mar 18, 2026 | — |
| 3 | OWNERSHIP DOCUMENT | 0001104659-26-030843 | Mar 18, 2026 | — |
| 3 | OWNERSHIP DOCUMENT | 0001104659-26-030838 | Mar 18, 2026 | — |
| 3 | OWNERSHIP DOCUMENT | 0001104659-26-030840 | Mar 18, 2026 | — |
| 3 | OWNERSHIP DOCUMENT | 0001104659-26-030842 | Mar 18, 2026 | — |
| 3 | OWNERSHIP DOCUMENT | 0001104659-26-030841 | Mar 18, 2026 | — |
| 3 | OWNERSHIP DOCUMENT | 0001104659-26-030835 | Mar 18, 2026 | — |
| 3 | OWNERSHIP DOCUMENT | 0001104659-26-030836 | Mar 18, 2026 | — |
| 3 | OWNERSHIP DOCUMENT | 0001104659-26-030834 | Mar 18, 2026 | — |
| 3 | OWNERSHIP DOCUMENT | 0001104659-26-030833 | Mar 18, 2026 | — |
| 3 | OWNERSHIP DOCUMENT | 0001104659-26-030837 | Mar 18, 2026 | — |
| S-8 | FORM S-8 | 0001104659-26-026472 | Mar 11, 2026 | — |
| SCHEDULE 13G | — | 0000315066-26-000646 | Mar 6, 2026 | — |
| 6-K | FORM 6-K | 0001104659-26-024095 | Mar 5, 2026 | — |
| SCHEDULE 13D | — | 0001193125-26-052946 | Feb 17, 2026 | — |
| 6-K | FORM 6-K | 0001104659-26-012080 | Feb 9, 2026 | — |
| 424B4 | 424B4 | 0001104659-26-011523 | Feb 6, 2026 | — |
| CERT | — | 0001354457-26-000141 | Feb 5, 2026 | — |
| 8-A12B | FORM 8-A12B | 0001104659-26-009822 | Feb 3, 2026 | — |
| EFFECT | — | 9999999995-26-000416 | Jan 30, 2026 | — |
| F-1/A | F-1/A | 0001104659-26-007712 | Jan 29, 2026 | — |
| F-1 | F-1 | 0001104659-26-004558 | Jan 16, 2026 | — |
| DRS/A | — | 0001104659-25-122109 | Dec 17, 2025 | — |
| DRS/A | — | 0001104659-25-102694 | Oct 28, 2025 | — |
| DRS | — | 0001104659-24-073452 | Jun 20, 2024 | — |